It’s the time of year when the Fierce Biotech team sticks its shovel into fresh soil to bury another year’s worth of biotechs. Though the list is ritualistic, it’s hardly ceremonious. It marks the difficult decision many drug developers had to make after funds ran dry or scientific leads reached dead ends or both. And, […]